Primary NSCLC patient information
| Primary cells | Gender | Age (years) | Pathology | Immunohistochemistry | EGFR mutation |
|---|---|---|---|---|---|
| LS-1# | Male | 58 | Metastatic lung adenocarcinoma | TTF1[+], Napsin A[+], CK7[+], CK20[+], GFAP[−], Ki-67[+,15%-20%] | EGFR (wt) |
| LS-2# | Female | 52 | Peripulmonary moderately to poorly differentiated lung adenocarcinoma | CK7[+], CK20[−], CK5/6[−], P63[−], Napsin A[+], TTF1[+], ALK[0], Ki-67[+,2%-5%] | EGFR (20 lns) |
| LS-3# | Male | 71 | Invasive lung adenocarcinoma | ROS1(−), c-Met(++,80%), CK5/6(−), CK7(+), P40(−), P63(−), TTF1(+), Napsin A(+) | EGFR (wt) |
| LS-4# | Male | 71 | Invasive lung adenocarcinoma | CK20(−), CDX-2(−), c-Met(+,10%), CK5/6(−), ROS1(+,5%), CK7(−), P40(−), P63(−), TTF1(+), Napsin A(+), ALK(D5F3)(−) | EGFR (wt) |
EGFR, epidermal growth factor receptor; wt, wild-type.